• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Updated Treatment Recommendation on Use of Cabotegravir and Rilpivirine for People With HIV From the IAS-USA Guidelines Panel.

作者信息

Sax Paul E, Thompson Melanie A, Saag Michael S

机构信息

Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

AIDS Research Consortium of Atlanta, Atlanta, Georgia.

出版信息

JAMA. 2024 Mar 26;331(12):1060-1061. doi: 10.1001/jama.2024.2985.

DOI:10.1001/jama.2024.2985
PMID:38427337
Abstract
摘要

相似文献

1
Updated Treatment Recommendation on Use of Cabotegravir and Rilpivirine for People With HIV From the IAS-USA Guidelines Panel.美国国际艾滋病学会（IAS-USA）指南小组关于使用卡博特韦和利匹韦林治疗HIV感染者的最新治疗建议
JAMA. 2024 Mar 26;331(12):1060-1061. doi: 10.1001/jama.2024.2985.
2
Cabotegravir-rilpivirine treatment initiation in a nonvirologically suppressed patient.在一名病毒学未得到抑制的患者中开始使用卡博特韦-利匹韦林治疗。
AIDS. 2022 Aug 1;36(10):1475-1476. doi: 10.1097/QAD.0000000000003273.
3
The potential role of long-acting injectable cabotegravir-rilpivirine in the treatment of HIV in sub-Saharan Africa: a modelling analysis.长效注射用卡替拉韦-利匹韦林在撒哈拉以南非洲治疗 HIV 的潜在作用：建模分析。
Lancet Glob Health. 2021 May;9(5):e620-e627. doi: 10.1016/S2214-109X(21)00025-5. Epub 2021 Mar 23.
4
Monthly injectable cabotegravir/rilpivirine to manage HIV infection in adults.每月注射用卡替拉韦/利匹韦林治疗成人 HIV 感染。
J Am Assoc Nurse Pract. 2022 Jul 1;34(7):918-923. doi: 10.1097/JXX.0000000000000729.
5
CD4+/CD8+ improvement after switch from a second-generation integrase inhibitor regimen to long-acting cabotegravir and rilpivirine.从第二代整合酶抑制剂方案转换为长效卡替拉韦和利匹韦林后 CD4+/CD8+ 的改善。
AIDS. 2024 Nov 1;38(13):1890-1892. doi: 10.1097/QAD.0000000000003984. Epub 2024 Sep 26.
6
Contribution of cabotegravir + rilpivirine long-acting for the treatment of HIV-1 infection.卡替拉韦/利匹韦林长效用于治疗 HIV-1 感染的贡献。
Farm Hosp. 2022 Jul 4;46(4):208-214.
7
Long-acting Injectable Cabotegravir/Rilpivirine Effective in a Small Patient Cohort With Virologic Failure on Oral Antiretroviral Therapy.长效注射用卡替拉韦/利匹韦林在口服抗逆转录病毒治疗失败的小患者队列中有效。
Clin Infect Dis. 2024 Jan 25;78(1):122-124. doi: 10.1093/cid/ciad511.
8
Cabotegravir and Rilpivirine.卡博特韦和利匹韦林。
Am J Health Syst Pharm. 2021 May 24;78(11):925-931. doi: 10.1093/ajhp/zxab088.
9
Long-acting cabotegravir/rilpivirine for HIV-1 treatment: real-world evaluation of barriers to implementation.用于HIV-1治疗的长效卡博特韦/利匹韦林：实施障碍的真实世界评估
AIDS. 2023 Mar 15;37(4):689-691. doi: 10.1097/QAD.0000000000003476.
10
Are we ready for long-acting? A feasibility evaluation of long-acting cabotegravir-rilpivirine in clinical practice.长效药物准备好了吗？长效卡替拉韦-利匹韦林在临床实践中的可行性评估。
J Med Virol. 2022 Oct;94(10):4970-4974. doi: 10.1002/jmv.27890. Epub 2022 Jun 9.

引用本文的文献

1
Clinical consequences of delaying implementation of long-acting antiretroviral therapy for people with HIV and persistent viremia in the US.在美国，延迟对患有HIV且持续病毒血症的患者实施长效抗逆转录病毒疗法的临床后果。
Clin Infect Dis. 2025 Aug 4. doi: 10.1093/cid/ciaf428.
2
Optimizing the Use of Cabotegravir Plus Rilpivirine Long-acting Therapy in HIV Care: Evidence, Implementation, and Unanswered Questions.优化卡博特韦加rilpivirine长效疗法在HIV治疗中的应用：证据、实施及未解决的问题
Open Forum Infect Dis. 2025 Jul 3;12(7):ofaf368. doi: 10.1093/ofid/ofaf368. eCollection 2025 Jul.
3
Long-Term Real-World Use of Cabotegravir/Rilpivirine: Adherence and Virological Efficacy over a 44-Month Observation Period.
卡博特韦/利匹韦林的长期真实世界使用情况：44个月观察期内的依从性和病毒学疗效
Infect Dis Ther. 2025 Jul 8. doi: 10.1007/s40121-025-01178-3.
4
Potential impact and cost-effectiveness of long-acting injectable lenacapavir plus cabotegravir as HIV treatment in Africa.长效注射用伦那卡韦联合卡博特韦作为非洲地区HIV治疗方法的潜在影响和成本效益
Nat Commun. 2025 Jul 1;16(1):5760. doi: 10.1038/s41467-025-60752-y.
5
HIV Viral Suppression With Unintentional Lenacapavir Monotherapy in Adherence-Challenged Patients: A Case Series.依从性差的患者接受无意的长效卡帕韦单药治疗实现HIV病毒抑制：病例系列
Open Forum Infect Dis. 2025 Jun 11;12(6):ofaf330. doi: 10.1093/ofid/ofaf330. eCollection 2025 Jun.
6
Treatment of Advanced HIV in the Modern Era.现代时代晚期HIV的治疗
Drugs. 2025 May 12. doi: 10.1007/s40265-025-02181-1.
7
Clinical Outcomes and Perspectives of People With Human Immunodeficiency Virus Type 1 Twelve Months After Initiation of Long-acting Cabotegravir and Rilpivirine in an Observational Real-world US Study (BEYOND).美国一项观察性真实世界研究（BEYOND）中，1型人类免疫缺陷病毒感染者在开始使用长效卡博特韦和利匹韦林十二个月后的临床结局与展望
Open Forum Infect Dis. 2025 Apr 19;12(5):ofaf220. doi: 10.1093/ofid/ofaf220. eCollection 2025 May.
8
Cost-effectiveness of long-acting cabotegravir/rilpivirine for people with HIV and adherence challenges at the Ward 86 clinic: an intermediate outcome analysis.长效卡博特韦/利匹韦林用于第86病房诊所面临依从性挑战的HIV感染者的成本效益：一项中间结局分析
AIDS. 2025 Jun 1;39(7):899-904. doi: 10.1097/QAD.0000000000004145. Epub 2025 Feb 4.
9
Use of long-acting injectable cabotegravir/rilpivirine in people with HIV and adherence challenges.长效注射用卡博特韦/利匹韦林在有HIV且存在依从性挑战的人群中的应用。
Curr Opin HIV AIDS. 2025 Jan 1;20(1):11-18. doi: 10.1097/COH.0000000000000904. Epub 2024 Nov 8.
10
Learning from the first: a qualitative study of the psychosocial benefits and treatment burdens of long-acting cabotegravir/rilpivirine among early adopters in three U.S. clinics.从首例开始学习：在美国三家诊所中，早期使用者对长效卡博特韦/利匹韦林的心理社会获益和治疗负担的定性研究。
J Int AIDS Soc. 2024 Nov;27(11):e26394. doi: 10.1002/jia2.26394.